- EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic - SOUTH SAN FRANCISCO, Calif. , May 26, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that

- Patient enrollment completed in Arm A in the Phase 2 study of praluzatamab ravtansine in breast cancer, initial data for both Arms A and B on track for second half of 2022 - - Phase 2 expansion study of CX-2029 ongoing, patient enrollment completed for squamous non-small cell lung cancer cohort

SOUTH SAN FRANCISCO, Calif. , April 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close of

SOUTH SAN FRANCISCO, Calif. , April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett , M.D. is retiring from its board of directors, effective when his current term

SOUTH SAN FRANCISCO, Calif. , March 23, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Frederick W. Gluck is retiring from its board of directors, effective June 30th, 2022 .

SOUTH SAN FRANCISCO, Calif. , March 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that preclinical data supporting the ongoing development of its conditionally activated cytokine program

- Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer (sqNSCLC) reported in 2021 - - First-in-human study of CX-904 in advanced solid tumors to be initiated in first half of 2022 - - Initial data for Arms A and B in Phase 2 study of praluzatamab

SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy , D.Phil ., chief executive officer and chairman, will participate in a virtual panel

SOUTH SAN FRANCISCO, Calif. , Feb. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022, after

SOUTH SAN FRANCISCO, Calif. , Feb. 16, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that on February 16, 2022 , the Company granted nine new employees options to purchase a total of 189,400